MannKind Corporation has announced that the INHALE-1 Study of Afrezza® has officially begun enrollment for those aged 4-17 living with T1D/T2D.
Afrezza (insulin human) Inhalation Powder is the only inhaled ultra rapid-acting mealtime insulin and is FDA-approved for adults (18+) with T1D or T2D. The multi-center study will assess the efficacy and safety of Afrezza vs. multiple daily injections of insulin, both in combination with basal insulin.
For more details about the study and if your child may be eligible, please visit go.afrezza.com/INHALE1.